The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Therasense are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Therasense has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical and fundamental indicators, Therasense is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Quick Ratio
0.13
Fifty Two Week Low
0.0028
Fifty Two Week High
2.9200
Therasense
Therasense Relative Risk vs. Return Landscape
If you would invest 0.01 in Therasense on October 31, 2025 and sell it today you would earn a total of 0.00 from holding Therasense or generate 0.0% return on investment over 90 days. Therasense is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Therasense, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Therasense Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Therasense for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Therasense can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Therasense generated a negative expected return over the last 90 days
Therasense has some characteristics of a very speculative penny stock
Therasense has a very high chance of going through financial distress in the upcoming years
Therasense currently holds 2.9 M in liabilities. Therasense has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Therasense until it has trouble settling it off, either with new capital or with free cash flow. So, Therasense's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Therasense sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Therasense to invest in growth at high rates of return. When we think about Therasense's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 353.26 K. Net Loss for the year was (7.75 M) with profit before overhead, payroll, taxes, and interest of 256.68 K.
Therasense currently holds about 127.82 K in cash with (5.54 M) of positive cash flow from operations.
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Therasense Pink Sheet often depends not only on the future outlook of the current and potential Therasense's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Therasense's indicators that are reflective of the short sentiment are summarized in the table below.
Float Shares
1.01B
Average Daily Volume Last 10 Day
1.1M
Average Daily Volume In Three Month
1.02M
Therasense Fundamentals Growth
Therasense Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Therasense, and Therasense fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Therasense Pink Sheet performance.
Assessing Therasense's fundamental ratios provides investors with valuable insights into Therasense's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Therasense is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.
Things to note about Therasense performance evaluation
Checking the ongoing alerts about Therasense for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Therasense help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Therasense generated a negative expected return over the last 90 days
Therasense has some characteristics of a very speculative penny stock
Therasense has a very high chance of going through financial distress in the upcoming years
Therasense currently holds 2.9 M in liabilities. Therasense has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Therasense until it has trouble settling it off, either with new capital or with free cash flow. So, Therasense's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Therasense sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Therasense to invest in growth at high rates of return. When we think about Therasense's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 353.26 K. Net Loss for the year was (7.75 M) with profit before overhead, payroll, taxes, and interest of 256.68 K.
Therasense currently holds about 127.82 K in cash with (5.54 M) of positive cash flow from operations.
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Evaluating Therasense's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Therasense's pink sheet performance include:
Analyzing Therasense's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Therasense's stock is overvalued or undervalued compared to its peers.
Examining Therasense's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Therasense's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Therasense's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Therasense's pink sheet. These opinions can provide insight into Therasense's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Therasense's pink sheet performance is not an exact science, and many factors can impact Therasense's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Therasense Pink Sheet Analysis
When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.